biotech industry

Today’s episode is about the science of slowing down the aging process … and why one biotech company has found some success with dogs. Last November, the New York Times reported that a company called Loyal had reached a milestone in the development of safe life extension drugs for our pets. This drug, which is called LOY-1, works to slow the aging process in large breeds. But Loyal's work holds major promise for helping all dogs live longer. It could even crack open some of the mysteries of mammalian aging, which could lead to discoveries that extend the lives of humans. Today's guest is the CEO and founder of Loyal, Celine Halioua. We talk about her experience as a female biotech founder, the weird economics of pharma, the ethics of life extension, the science of why big dogs die young, her theories for how to slow down the aging process in dogs big and small, and the possibility spillover benefits for humans who would like a few more years with their family and friends. If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com. Host: Derek Thompson Guest: Celine Halioua Producer: Devon Baroldi Learn more about your ad choices. Visit podcastchoices.com/adchoices

Ginkgo Bioworks is using DNA as code to digitize the cell programming revolution. Ginkgo is using AI and synthetic biology to keep the next pandemic at bay, and accelerate our production capabilities for medicine, food, and agriculture. Ginkgo’s co-founder and CEO Jason Kelly joins hosts Sarah Guo and Elad Gil to discuss bioengineering protein as a foundational model, specialized data learning from an evolutionary perspective, what we need to prepare for a future pandemic, and more. Jason has served as a member of our board of directors since Ginkgo’s founding in 2008. He has also served as a director of CM Life Sciences II Inc. (Nasdaq: CMII), a special purpose acquisition company with a focus on the life sciences sector, since its initial public offering in February 2021. Jason holds a Ph.D. in Biological Engineering and a B.S. in Chemical Engineering and Biology from the Massachusetts Institute of Technology. Show Links:  Jason Kelly - Co-founder & CEO of Ginkgo Bioworks | LinkedIn   Ginkgo Bioworks The Plausibility of Life: Resolving Darwin's Dilemma Sign up for new podcasts every week. Email feedback to show@no-priors.com Follow us on Twitter: @NoPriorsPod | @Saranormous | @EladGil | @jrkelly Show Notes:  (0:00:00) - The Difference Between Software Engineering and Biological Engineering (0:06:51) - Abstractions and Infrastructure in Synthetic Bio (0:09:23) - The Role of AI, Foundation Models that Speak Biology (0:13:17) - AWS for Cell Engineering (0:17:52) - Where are the AI-discovered Drugs? And Data at Gingko (0:19:12) - Pandemic Response and Biosecurity in the Age of AI (0:22:47) - The Likelihood of Existential AI Risk from Lone Actors Harnessing Viruses, and The Need for Defense-in-Depth (0:31:47) - Will Progress in AI Be Biologically Inspired? And Evolution

Jason opens with a Founder University segment on "Startup Math" (1:48), then interviews Zymergen CEO Josh Hoffman on Biofacturing (16:45), how DNA sequencing & machine learning are enabling materials science advancements (26:35), what human capital is needed for the industry (42:53) & more. Pod Notes: http://bit.ly/1231notes